secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2023-04-28T23:59:59+00:00
Accession:  0001193125-23-124381
Event type: other
Sentiment:  neutral
Materiality: 0.00
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharmaceuticals adopts amended bylaws effective June 8, 2023
----------------------------------------------------------------

- Amended and Restated Bylaws approved by Board on April 24, 2023, effective at 2023 annual meeting.
- Updates advance notice procedures for director nominations, including Rule 14a-19 compliance evidence requirement.
- Revises provisions on stockholder meetings, board action by written consent, and director/committee matters to conform to Delaware law.
- Also updates various provisions to conform to recent amendments to DGCL and makes ministerial clarifications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000119312523124381/0001193125-23-124381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000119312523124381/d452268d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-124381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer